Es gab 50 kürzliche Insider-Transaktionen für Q32 Bio Inc. (QTTB), darunter 24 Käufe und 25 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $2.66M und die gesamten Insider-Verkäufe auf $4.64M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Morrison Jodie Pope, Kalowski Lee, Violette Shelia M.. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — QTTB
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-02-25 |
Morrison Jodie Pope |
CEO |
Informierter Verkauf |
9,896 |
$4.51 |
$44.67K |
89,104 |
| 2026-02-25 |
Kalowski Lee |
CFO and President |
Informierter Verkauf |
3,995 |
$4.51 |
$18.04K |
35,943 |
| 2026-02-25 |
Violette Shelia M. |
Chief Scientific Officer |
Informierter Verkauf |
2,815 |
$4.51 |
$12.71K |
55,569 |
| 2026-02-24 |
Morrison Jodie Pope |
CEO |
RSU-Zuteilung |
132,000 |
- |
- |
221,104 |
| 2026-02-24 |
Kalowski Lee |
CFO and President |
RSU-Zuteilung |
53,250 |
- |
- |
89,193 |
| 2026-02-24 |
Violette Shelia M. |
Chief Scientific Officer |
RSU-Zuteilung |
37,500 |
- |
- |
93,069 |
| 2026-01-15 |
Laporte Kathleen |
Director |
RSU-Zuteilung |
23,272 |
$3.60 |
$83.78K |
23,272 |
| 2026-01-15 |
Lundberg Sven Ante |
Director |
RSU-Zuteilung |
20,363 |
$3.60 |
$73.31K |
20,363 |
| 2026-01-15 |
Grayzel David S. |
Director |
RSU-Zuteilung |
16,363 |
$3.60 |
$58.91K |
16,363 |
| 2025-12-02 |
Morrison Jodie Pope |
CEO |
Informierter Verkauf |
22,506 |
$3.46 |
$77.87K |
99,000 |
| 2025-12-02 |
Kalowski Lee |
CFO and President |
Informierter Verkauf |
9,072 |
$3.46 |
$31.4K |
39,938 |
| 2025-10-23 |
Laporte Kathleen |
Director |
RSU-Zuteilung |
53,521 |
$2.80 |
$149.86K |
53,521 |
| 2025-10-23 |
Thistle Mary |
Director |
RSU-Zuteilung |
53,521 |
$2.80 |
$149.86K |
53,521 |
| 2025-10-23 |
Iwicki Mark T |
Director |
RSU-Zuteilung |
53,521 |
$2.80 |
$149.86K |
53,521 |
| 2025-10-23 |
Tzianabos Arthur |
Director |
RSU-Zuteilung |
53,521 |
$2.80 |
$149.86K |
53,521 |
| 2025-10-23 |
Manke Isaac |
Director |
RSU-Zuteilung |
53,521 |
$2.80 |
$149.86K |
53,521 |
| 2025-10-23 |
Lundberg Sven Ante |
Director |
RSU-Zuteilung |
53,521 |
$2.80 |
$149.86K |
53,521 |
| 2025-10-23 |
Grayzel David S. |
Director |
RSU-Zuteilung |
53,521 |
$2.80 |
$149.86K |
53,521 |
| 2025-10-23 |
Xu Diyong |
Director |
RSU-Zuteilung |
53,521 |
$2.80 |
$149.86K |
53,521 |
| 2025-08-26 |
Morrison Jodie Pope |
CEO |
Informierter Verkauf |
10,494 |
$1.80 |
$18.9K |
121,506 |
| 2025-08-26 |
Kalowski Lee |
CFO and President |
Informierter Verkauf |
4,240 |
$1.80 |
$7.64K |
49,010 |
| 2025-08-26 |
Violette Shelia M. |
Chief Scientific Officer |
Informierter Verkauf |
2,990 |
$1.80 |
$5.38K |
58,384 |
| 2025-02-24 |
Thistle Mary |
Director |
Aktienrückgabe |
12,767 |
$16.82 |
$214.74K |
- |
| 2025-02-24 |
Iwicki Mark T |
Director |
Aktienrückgabe |
25,534 |
$16.82 |
$429.48K |
- |
| 2025-02-24 |
Morrison Jodie Pope |
CEO |
Aktienrückgabe |
152,700 |
$7.50 |
$1.15M |
- |
| 2025-02-24 |
Lundberg Sven Ante |
Director |
Aktienrückgabe |
12,767 |
$16.82 |
$214.74K |
- |
| 2025-02-24 |
Grayzel David S. |
Director |
Aktienrückgabe |
18,595 |
$3.20 |
$59.5K |
- |
| 2025-02-24 |
Campagna Jason |
Chief Medical Officer |
Aktienrückgabe |
70,687 |
$16.82 |
$1.19M |
- |
| 2025-02-24 |
Xu Diyong |
Director |
Aktienrückgabe |
12,767 |
$16.82 |
$214.74K |
- |
| 2025-02-24 |
Violette Shelia M. |
Chief Scientific Officer |
Aktienrückgabe |
13,305 |
$7.29 |
$96.99K |
- |
| 2025-02-24 |
Laporte Kathleen |
Director |
Aktienrückgabe |
1,947 |
$7.29 |
$14.19K |
- |
| 2025-02-24 |
Tzianabos Arthur |
Director |
Aktienrückgabe |
12,767 |
$16.82 |
$214.74K |
- |
| 2025-02-24 |
Kalowski Lee |
CFO and President |
Aktienrückgabe |
16,901 |
$17.08 |
$288.67K |
- |
| 2025-02-24 |
Manke Isaac |
Director |
Aktienrückgabe |
12,767 |
$16.82 |
$214.74K |
- |
| 2025-01-15 |
Lundberg Sven Ante |
Director |
RSU-Zuteilung |
23,140 |
$3.20 |
$74.05K |
23,140 |
| 2025-01-15 |
Grayzel David S. |
Director |
RSU-Zuteilung |
18,595 |
$3.20 |
$59.5K |
18,595 |
| 2025-01-15 |
Manke Isaac |
Director |
RSU-Zuteilung |
19,008 |
$3.20 |
$60.83K |
19,008 |
| 2024-10-15 |
Violette Shelia M. |
Chief Scientific Officer |
Optionsausübung |
6,000 |
$7.29 |
$43.74K |
23,874 |
| 2024-10-11 |
Violette Shelia M. |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
4,361 |
$3.12 |
$13.61K |
- |
| 2024-10-08 |
Violette Shelia M. |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
13,300 |
$3.12 |
$41.5K |
213 |
| 2024-09-25 |
Lundberg Sven Ante |
Director |
RSU-Zuteilung |
1,316 |
$44.40 |
$58.43K |
1,316 |
| 2024-04-01 |
Grayzel David S. |
Director |
RSU-Zuteilung |
2,569 |
$18.00 |
$46.24K |
2,569 |
| 2024-04-01 |
Manke Isaac |
Director |
RSU-Zuteilung |
2,627 |
$18.00 |
$47.29K |
2,627 |
| 2024-03-25 |
Tzianabos Arthur |
Director |
Optionsausübung (Verkauf) |
1,095 |
- |
- |
- |
| 2024-03-25 |
Orbimed Advisors Llc |
10 Percent Owner |
Unbekannt |
- |
- |
- |
2,252,987 |
| 2024-03-25 |
Laporte Kathleen |
Director |
Veräußerung |
1,947 |
$7.29 |
$14.19K |
- |
| 2024-03-25 |
Laporte Kathleen |
Director |
RSU-Zuteilung |
12,767 |
$16.82 |
$214.74K |
12,767 |
| 2024-03-25 |
Thistle Mary |
Director |
RSU-Zuteilung |
12,767 |
$16.82 |
$214.74K |
12,767 |
| 2024-03-25 |
Iwicki Mark T |
Director |
Veräußerung |
7,615 |
$7.29 |
$55.51K |
- |
| 2024-03-25 |
Iwicki Mark T |
Director |
RSU-Zuteilung |
25,534 |
$16.82 |
$429.48K |
25,534 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
